business enterprise
Regulated Claims Move Their Rules Into the Data Model
A deployed pharmaceutical tool reports stronger audience, content and quality targeting after compliance context moved from prompts into structured retrieval.
Summary
A deployed pharmaceutical tool reports stronger audience, content and quality targeting after compliance context moved from prompts into structured retrieval.
A production case study compares prompt-level rules with a Golden Data Model covering 1,867 pharmaceutical claims across four products. The structured retrieval layer attaches references, audience labels, material type, usage history, linked text variants and a six-dimension quality score before generation. Across six product-audience segments, the authors report improvements in intended indication, content type, target audience, quality score and claim reuse, alongside a 29.5 percent reduction in weekly API cost. The paper labels this descriptive deployment evidence; it does not establish clinical efficacy or regulatory approval.
Why it matters
A deployed pharmaceutical tool reports stronger audience, content and quality targeting after compliance context moved from prompts into structured retrieval.
Limits and context
- The paper labels this descriptive deployment evidence; it does not establish clinical efficacy or regulatory approval.
Key claims
A deployed pharmaceutical tool reports stronger audience, content and quality targeting after compliance context moved from prompts into structured retrieval.
Qualification: The paper labels this descriptive deployment evidence; it does not establish clinical efficacy or regulatory approval.
Evidence: source-2026-10-24-007
Sources
- arXiv preprint 2610.31519, original v1arXiv · primary research
Corrections
No corrections have been recorded for this story.